Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab + Venetoclax + Azacitidine in Newly Diagnosed AML
NCT06384261Phase 2Active, not recruiting
- Sponsor
- OncoVerity
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of cusatuzumab in acute myeloid leukemia (AML), sponsored by OncoVerity. Started Jul 2024; status: active, not recruiting.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06384261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384261.